Cretostimogene Grenadenorepvec Produces Durable Responses in High-Risk NMIBC
Cretostimogene grenadenorepvec can produce durable complete responses in patients with high-risk non-muscle invasive bladder cancer that does not respond to Bacillus Calmette-Guérin therapy, a phase 3 trial suggests. Cretostimogene grenadenorepvec can produce durable complete responses in patients with high-risk NMIBC that does not respond to BCG therapy.